Pentacam Study Of Vault Changes After Tropicamide 1% And Cyclopentolate 1% Instillation In Myopic Eyes With Implantable Phakic Contact Lens

To evaluate the vault changes, anterior segment parameters, and intraocular pressure (IOP) after pharmacological mydriasis by tropicamide 1% and cyclopentolate 1% in moderate-to-high myopic eyes with Implantable Phakic Contact Lens (IPCL).

A prospective observational study 48 myopic eyes were implanted with IPCL V2.0 (Care group Sight Solutions, India) in Minia Opthalmology Department

Pharmacological mydriasis was done by tropicamide 1% and cyclopentolate 1%. The patients were divided into 2 groups, group 1 was dilated by tropicamide1 % and group 2 was dilated by cyclopentolate 1%. The Pentacam was used to evaluate the lens vault, anterior chamber depth (ACD), anterior chamber volume (ACV), pupil size, and endothelium-IPCL (end-IPCL). Also, IOP was evaluated and compared between both groups.

The Pentacam study of both groups revealed significant changes regarding the vault, ACD, ACV, and pupil size  with no significant difference in end-IPCL (p-value= 0.884 and 0.880) in groups 1 and 2 respectively. And no significant difference when comparing both groups with each other. Regarding IOP, there was a significant difference in both groups with no significant difference when comparing both groups with each other (p-value=.295)

Pharmacological mydriasis in myopic eyes implanted with IPCL results in changes in the vault, ACD, and ACV with no significant difference between tropicamide 1% and cyclopentolate 1%. Both medications caused IOP elevation to a similar value so there was a need to recheck IOP post dilatation preferably at 45 minutes. So mydriasis with either tropicamide 1 % or cyclopentolate 1 % was relatively safe in eyes with IPCL implantation.